PTO/SB/08 (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Substitute for form 1449/PTO Complete if Known INFORMATION DISCLOSURE **Application Number** 10/567,328 STATEMENT BY APPLICANT 8/6/2004 **Filing Date** AUG 2 1 Makoto SAWADA **First Named Inventor** Date Submitted: August 21, 2007 Art Unit <del>'drassigned</del> (use as many sheets as necessary) **Examiner Name** <del>Unassigned</del> K ard Sheet of Attorney Docket Number 084335-0201

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

O14-					
Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> ( <i>if known</i> )	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	   T <sup>4</sup>
C1	WO 2004/015392 A2	2/19/2004	TARGETED MOLECULES CORP.		
		Code <sup>5</sup> (if known)	Code <sup>5</sup> (if known)	Code <sup>5</sup> (if known)  C1 WO 2004/015392 A2 2/19/2004 TARGETED MOLECULES	Code <sup>5</sup> ( <i>if known</i> ) Figures Appear  C1 WO 2004/015392 A2 2/19/2004 TARGETED MOLECULES

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. 1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue publisher, city and/or country where published.		T <sup>6</sup>
	C2	IMAI et al., "Migration activity of microglia and macrophages into rat brain," Neuroscience Letters, 1997, 237:49-52.	
	C3	KANG et al., "Stability of the Disulfide Bond in an Avidin-Biotin Linked Chimeric Peptide During in vivo Transcytosis Through Brain Endothelial Cells", Journal of Drug Targeting, 2000, Vol. 8, No. 6, pp. 425-434.	
	C4	PASQUALINI et al., "Organ targeting in vivo using phage display in vivo using phage display peptide libraries", Nature, 1996, Vol. 380, No. 6572, pp. 364-366.	
	C5	SAWADA et al., "Brain-specific gene expression by immortalized microglial cell-mediated gene transfer in the mammalian brain", FEBS Letters, 1998, Vol. 433, pp. 37-40.	
	C6	SCHWARZE, et al., "In vivo protein transduction: delivery of a biologically active protein into the mouse", Science, 1999, Vol. 285, No. 5433, pp. 1569-1572.	

Examiner Signature	/Kimberly Ballard/	Date Considered	05/25/2009

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.